1. Small-molecule non-peptide antagonists of the PACAP receptor attenuate acute restraint stress-induced anxiety-like behaviors in mice.
- Author
-
Shintani Y, Yamano Y, Kuta M, Takeshita R, Takuma K, Okada T, Toyooka N, Takasaki I, Miyata A, Kurihara T, Hashimoto H, and Hayata-Takano A
- Subjects
- Animals, Anxiety drug therapy, Fluoxetine, Mice, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I, Anti-Anxiety Agents pharmacology, Anti-Anxiety Agents therapeutic use, Pituitary Adenylate Cyclase-Activating Polypeptide pharmacology, Pituitary Adenylate Cyclase-Activating Polypeptide therapeutic use
- Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a highly conserved pleiotropic neuropeptide, implicated in emotional stress responses and anxiety-related disorders. Here, we examined whether our recently developed small-molecule non-peptide PACAP receptor antagonists could ameliorate anxiety-like behaviors induced by acute restraint stress in mice. The antagonists PA-9 and its derivative PA-915 improved anxiety-like behaviors in mice subjected to restraint stress. An anxiolytic effect was observed with single acute dose, suggesting their fast-acting properties. PA-915 demonstrated a statistically significant anxiolytic effect whereas fluoxetine did not. These results indicate the potential of PAC1 antagonists as a novel treatment for anxiety., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this study., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF